1.
When and How Do I Use Neoadjuvant Chemotherapy for Breast Cancer?
by Rapoport, Bernardo L
Current treatment options in oncology, 2013-12-05, Vol.15 (1), p.86-98
2.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HE...
by Gianni, Luca, Dr
The lancet oncology, 2014, Vol.15 (6), p.640-647
3.
Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients
by Sanford, Rachel A
Annals of surgical oncology, 2015-12-17, Vol.23 (5), p.1515-1521
4.
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results fr...
by Krop, Ian E, Dr
The lancet oncology, 2017, Vol.18 (6), p.743-754
5.
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall...
by Diéras, Véronique, Dr
The lancet oncology, 2017, Vol.18 (6), p.732-742
6.
De-escalation of breast and axillary surgery in exceptional responders to neoadjuvant systemic treatment
by Heil, Joerg
The lancet oncology, 2021-04, Vol.22 (4), p.435-436
7.
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients with Cytologically Proven Node-positive Breast Cancer at Diagnosis
by Park, Seho
Annals of surgical oncology, 2013-05-05, Vol.20 (9), p.2858-2865
8.
Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
by Nguyen, Toan T
Annals of surgical oncology, 2018-07-05, Vol.25 (9), p.2596-2602
9.
Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells
by Coombs, Melanie R. Power
Cancer letters, 2016, Vol.380 (2), p.424-433
10.
Breast Cancer Biomarkers Before and After Neoadjuvant Chemotherapy: Does Repeat Testing Impact Therapeutic Management?
by Xian, Zhaoying
Human pathology, 2016, Vol.62, p.215-221
11.
Clinical and Pathological Response to Neoadjuvant Chemotherapy Based on Primary Tumor Reduction is Correlated to Survival in Hormone Receptor-Positive but not Hormone Receptor-Nega...
by Chen, Sheng
Annals of surgical oncology, 2014-07-11, Vol.22 (1), p.32-39
12.
Use of chemotherapy in elderly patients with early-stage triple-negative breast cancer
by Curigliano, Giuseppe
The lancet oncology, 2020-12, Vol.21 (12), p.1543-1545
13.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2...
by Cameron, David, Prof
The lancet oncology, 2017, Vol.18 (7), p.929-945
14.
Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism
by Shim, Joong Sup
Cancer letters, 2015, Vol.362 (1), p.106-115
15.
Treatment patterns and duration in post-menopausal women with HR+/HER2− metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010)...
by Macalalad, Alexander R
Current medical research and opinion, 2015-02, Vol.31 (2), p.263-273
16.
Functional relationship of SNP (Ala490Thr) of an epigenetic gene EZH2 results in the progression and poor survival of ER+/tamoxifen treated breast cancer patients
by Gautam, Nisha
Journal of genetics, 2021-11-16, Vol.100 (2)
17.
Cognitive Impairment after Chemotherapy Related to Atypical Network Architecture for Executive Control
by Piccirillo, Jay F
Oncology, 2015-05, Vol.88 (6), p.360-368
18.
Axillary Node Staging for Microinvasive Breast Cancer: Is It Justified?
by Lyons, John M
Annals of surgical oncology, 2012-05-11, Vol.19 (11), p.3416-3421
19.
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
by Nakatsukasa, Katsuhiko
Breast cancer (Tokyo, Japan), 2016-01-11, Vol.24 (1), p.63-68
20.
Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study)
by Futamura, Manabu
Breast cancer (Tokyo, Japan), 2021-04-03, Vol.28 (5), p.1023-1037
